$135.070
-0.014 (-0.01%)收盤時
APGE 資訊
APGE 事件
AbbVie Completes Acquisition of Apogee for Approximately $10.9B
AbbVie (ABBV) announced that it has completed its acquisition of Apogee Therapeutics (APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9B. "The completion of the Apogee acquisition is an important step in further strengthening AbbVie's leadership in immunology and advancing our long-term growth strategy," said Robert A. Michael, chairman and chief executive officer, AbbVie. "By combining Apogee's innovative science with AbbVie's proven development, regulatory and commercial capabilities, we aim to accelerate these programs and bring promising new treatment options to patients living with serious inflammatory and immunological diseases. We are excited to welcome the talented Apogee team to AbbVie and build on their important work."
Stifel Downgrades Apogee Therapeutics to Hold with Price Target of $135
Stifel downgraded Apogee Therapeutics (APGE) to Hold from Buy with a price target of $135, up from $133, after the company entered into an agreement to be acquired by AbbVie (ABBV) for $135.11 per share in cash. The firm considers this to be "a great outcome" for Apogee and its shareholders, the analyst tells investors.
Guggenheim Downgrades Apogee Therapeutics to Neutral
Guggenheim downgraded Apogee Therapeutics (APGE) to Neutral from Buy after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share in cash.
RBC Raises Apogee Price Target to $135
RBC Capital analyst Brian Abrahams raised the firm's price target on Apogee Therapeutics (APGE) to $135 from $97 and keeps a Sector Perform rating on the shares after AbbVie (ABBV) announced its acquisition of Apogee for $135.11 per share in cash or $10.9B. The firm's higher price target reflects the deal price and likelihood the deal ultimately goes through, the analyst tells investors in a research note, adding that while competitive offers are possible as there are a number of key players in the space, Apogee likely ran a process that would have already incorporated other potential external interest.
BofA Moves to No Rating on Apogee Therapeutics After AbbVie Acquisition
BofA moved to No Rating on Apogee Therapeutics (APGE) after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share in cash. AbbVie sees strategic alignment with complementing their current immunology portfolio while accelerating their presence in the respiratory space, notes the analyst, who says Apogee is no longer trading on fundamentals given the deal announcement.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。